首页 曼恩凯德(usMNKD)-基本信息

曼恩凯德(usMNKD)-基本信息

日报更新时间:04-10 10:00

周报更新时间:04-11 03:39

行情信息

今开价:4.3

最高价:4.34

成交量:2860225.0

昨收价:4.32

最低价:4.16

最新价:4.24

行情图标
概要信息

中文名称:曼恩凯德


英文名称:MannKind


行业:医疗


简介:Mannkind Corporation于1991年2月14日在美国特拉华州注册成立


电话:1-661-7755300


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

曼恩凯德生物医疗公司是一家专注在美国从事糖尿病治疗药物的开发、改进及商业化应用的生物制药公司,主要产品AFREZZA吸入粉末,是针对1型和2型糖尿病人的血糖控制的胰岛素类产品,也是目前市场上唯一的非注射胰岛素,2014年6月获FDA批准上市。新闻回顾(2014-6-27):在被FDA拒绝两次之后,今天Mannkind的速效吸入胰岛素Afrezza终于被FDA批准用于成人糖尿病治疗。作为饭前胰岛素,Afrezza可用于一型和二型糖尿病,但对于一型糖尿病Afrezza需和长效胰岛素联用。慢性呼吸性疾病患者禁用此药,吸烟者慎用此药。由于糖尿病是当今第一大疾病,也是美国药物开支的第一大户,有专家预计Afrezza峰值销售可达20亿美元。

交易日期 交易人 职位 类型 交易份额 价格
2019-02-19 Barton (Courtney) Officer Buy 12584 --
2019-02-19 McCauley (Patrick J.D.) Officer Buy 40268 --
2019-02-19 Kocinsky (Joseph) Chief Technology Officer Buy 38507 --
2019-02-19 Tross Stuart A Officer Buy 36745 --
2019-02-19 Ingram (Elizabeth Garrett) Officer Buy 11871 --
2019-02-19 Thomson (David B) General Counsel Buy 43616 --
2019-02-19 Castagna (Michael E) Chief Executive Officer Buy 60403 --
2019-02-19 Binder (Steven B) Chief Financial Officer Buy 40268 --
2019-01-30 McCauley (Patrick J.D.) Officer Buy 5000 1.07
2019-01-30 Barton (Courtney) Officer Buy 5000 1.07
2019-01-30 Castagna (Michael E) Chief Executive Officer Buy 5000 1.07
2019-01-30 Kendall (David M) Officer Buy 5000 1.07
2019-01-30 Ingram (Elizabeth Garrett) Officer Buy 5000 1.07
2019-01-30 Binder (Steven B) Chief Financial Officer Buy 1860 1.07
2019-01-30 Tross Stuart A Officer Buy 5000 1.07
2018-12-22 Tross Stuart A Officer Sell 2044 1.09
2018-11-13 Tross Stuart A Officer Buy 14124 1.77
2018-11-13 McCauley (Patrick J.D.) Officer Buy 14124 1.77
2018-11-13 Kendall (David M) Officer Buy 2824 1.77
2018-11-13 Castagna (Michael E) Chief Executive Officer Buy 25000 1.77
2018-08-27 Thomson (David B) General Counsel Sell 278 1.12
2018-08-20 Thomson (David B) General Counsel Sell 167 1.11
2018-08-01 Binder (Steven B) Chief Financial Officer Buy 1760 1.31
2018-08-01 Barton (Courtney) Officer Buy 5000 1.31
2018-08-01 Tross Stuart A Officer Buy 5000 1.31

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Charles Schwab Investment Management Inc 969635 0.52% 138489 16.66% 2019-03-31
State Street Corporation 2682145 1.43% 430131 19.10% 2019-03-31
Raging Capital Management LLC 2955707 1.57% -489264 -14.20% 2019-03-31
D. E. Shaw & Co LP 3083881 1.64% 1869543 153.96% 2019-03-31
Northern Trust Investments Inc 3266347 1.74% 117364 3.73% 2019-07-31
Vanguard Investments Australia Ltd 5148090 2.74% -- -- 2019-07-31
BlackRock Fund Advisors 8218240 4.38% 2565 0.03% 2019-07-31
Vanguard Group Inc 9301059 4.95% 1055241 12.80% 2019-03-31
BlackRock Inc 13081856 6.97% 1249452 10.56% 2019-03-31
Morgan Stanley - Brokerage Accounts 2508114 1.34% 1621199 182.79% 2019-03-31
Geode Capital Management, LLC 2152020 1.15% -1180188 -35.42% 2019-03-31
Fidelity Management & Research Company 1988095 1.06% 148893 8.10% 2019-07-31
BlackRock 1111696 0.59% 56853 5.39% 2019-07-31
Fidelity SelectCo, LLC 1402861 0.75% -398539 -22.12% 2019-07-31
Fidelity Management and Research Company 1404381 0.75% 1520 0.11% 2019-03-31
FMR Inc 1404381 0.75% 1520 0.11% 2019-03-31
State Street Global Advisors 1520054 0.81% -- -- 2019-07-31
Millennium Management LLC 1618168 0.86% 1618168 -- 2019-03-31
Northern Trust Investments N A 1889945 1.01% 313494 19.89% 2019-03-31
Northern Trust Corp 1889945 1.01% 313494 19.89% 2019-03-31
CVI Holdings LLC 10716080 5.71% 10716080 -- 2018-12-31
BlackRock Asset Management Canada Ltd 3558912 1.90% -2182 -0.06% 2019-05-31
Scopia Management Inc 1666498 0.89% -- -- 2018-12-31
Highbridge Capital Management, LLC 2499491 1.33% 2499491 -- 2018-12-31
Deerfield Management Co 943298 0.50% 943298 -- 2018-12-31
AXA Equitable Funds Management Group, LLC 442574 0.24% -- -- 2019-02-28
Bank of New York Mellon Corp 433294 0.23% 35721 8.98% 2018-12-31
BNY Mellon Investment Management 389865 0.21% 35721 10.09% 2018-12-31
TIAA-CREF Investment Management LLC 500486 0.31% 189360 60.86% 2018-09-30
Teachers Advisors LLC 531844 0.33% 263078 97.88% 2018-09-30
Bridgeway Capital Management, Inc 387000 0.24% -- -- 2018-09-30
Morgan Stanley & Co Inc 399524 0.25% -569337 -58.76% 2018-06-30
BlackRock Institutional Trust Company NA 3218244 2.02% 1497091 86.98% 2018-06-30
Bruce & Co Inc 300000 0.22% 300000 -- 2018-06-30
Two Sigma Investments LLC 280800 0.22% 110400 64.79% 2018-03-31
Susquehanna Financial Group, LLLP 388145 0.27% -397373 -50.59% 2018-06-30
Cornerstone Wealth Management LLC 1900 0.36% 1900 -- 2018-06-30
State Street Corp 2180641 1.50% 2084570 2169.82% 2018-06-30
Sabby Management LLC 7801908 6.19% 7801908 -- 2018-04-05
BlueCrest Capital Management Ltd. 304858 0.24% 304858 -- 2018-03-31
Goldman, Sachs & Co. 304639 0.21% -1162386 -79.23% 2018-06-30
U.S. Home Corporation 265000 0.21% 63100 31.25% 2018-03-31
Creative Planning Inc 242632 0.19% 884 0.37% 2018-03-31
BMO Asset Management Inc 257560 0.20% 63000 32.38% 2018-03-31
J.P. Morgan Securities Inc 270190 0.21% 262911 3611.91% 2018-03-31
Teachers Advisors Inc 579892 0.40% 579892 -- 2018-06-30
Northern Trust Asset Management 339482 0.23% 339482 -- 2018-06-30
Morgan Stanley Smith Barney LLC 155869 0.12% 1732 1.12% 2018-03-31
Susquehanna International Group, LLP 785518 0.62% -1207132 -60.58% 2018-03-31
Dimensional Fund Advisors, Inc. 188171 0.16% 63633 51.10% 2017-12-31
BlackRock Advisors (UK) Ltd 189138 0.16% 135738 254.19% 2017-12-31
Hudson Bay Capital Management LP 304360 0.26% -251419 -45.24% 2017-12-31
Raymond James & Associates 156554 0.13% 55266 54.56% 2017-12-31
Zeke Capital Advisors, LLC 132100 0.11% 132100 -- 2017-12-31
Balyasny Asset Management LLC 619800 0.59% 216800 53.80% 2017-09-30
Element Capital Management LLC 161841 0.15% -100099 -38.21% 2017-09-30
GSA Capital Partners LLP 340420 0.33% -351500 -50.80% 2017-06-30
Sunrise Partners LLC 192200 0.18% 192200 -- 2017-06-30
California State Teachers Retirement Sys 684796 0.14% 4800 0.71% 2016-09-30
Migdal Mutual Funds Ltd 902771 0.20% -37993 -4.04% 2016-11-30
BlackRock Advisors LLC 1247825 0.26% -46264 -3.58% 2016-09-30
Group One Trading, LP 1718705 0.36% 1606158 1427.10% 2016-09-30
Psagot Investment House Ltd. 2000000 0.42% -- -- 2016-09-30
Government Pension Fund of Norway - Global 1582043 0.43% 1021735 182.35% 2013-12-31
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Russell 2000 Index Non-Lendable Fund E 376026 0.20% 33013 9.62% 2019-06-30
Vanguard Total Stock Market Index Fund 5148090 2.74% -- -- 2019-06-30
iShares Russell 2000 ETF 4090810 2.18% 8008 0.20% 2019-07-30
Vanguard Extended Market Index Fund 2383748 1.27% -- -- 2019-06-30
iShares Nasdaq Biotechnology ETF 1834844 0.98% -5444 -0.30% 2019-07-30
iShares Russell 2000 Growth ETF 1699580 0.91% -- -- 2019-07-30
State Street Russell Small Cap 727592 0.39% -- -- 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 708342 0.38% -- -- 2019-06-30
State Street Russell Small/Mid Cap 702354 0.37% -- -- 2019-06-30
Fidelity 647896 0.35% 147807 29.56% 2019-04-30
NT R2000 Index Fund - NL 646638 0.34% 26018 4.19% 2019-06-30
Schwab US Small-Cap ETF 504991 0.27% 432 0.09% 2019-07-31
NT R2000 Growth Index Fund - Lending 494794 0.26% 9800 2.02% 2019-06-30
Northern Trust Russell 2000 Index DC NL 490906 0.26% 18141 3.84% 2019-06-30
iShares Micro-Cap ETF 476446 0.25% -- -- 2019-07-30
Schwab Small Cap Index Fund 390146 0.21% 61196 18.60% 2019-06-30
ALPS Medical Breakthroughs ETF 389343 0.21% -- -- 2019-07-31
Bridgeway Ultra Small Company Market Fd 387000 0.21% -- -- 2019-03-31
Vanguard Health Care Index Fund 353910 0.19% 111724 46.13% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 3294756 1.75% -5526 -0.17% 2019-05-30
BlackRock Russell 2000 251426 0.13% 49530 24.53% 2019-03-31
BlackRock Extended Equity Market 316552 0.17% 83145 35.62% 2019-03-31
TIAA-CREF Small-Cap Blend 212106 0.11% -- -- 2019-01-31
Vanguard Instl Total Stock Market Idx Fd 232977 0.12% 28700 14.05% 2019-02-28
The Vanguard - Russell 2000 Grwth Idx CF 251099 0.13% 3777 1.53% 2019-02-28
AXA 2000 Managed Volatility Portfolio 212046 0.11% -- -- 2018-12-31
iShares Core S&P Total US Stock Mkt ETF 237768 0.13% -- -- 2019-02-28
Master Small Cap Index Series 175831 0.09% -- -- 2019-01-31
Vanguard Russell 2000 Index Fund 167355 0.09% 2149 1.30% 2019-01-31
iShares Russell 2000 Small-Cap Index Fd 175831 0.11% -- -- 2018-12-31
LVIP SSgA Small Cap Index Fund 152500 0.10% -- -- 2018-09-30
Fidelity Advisor 398539 0.25% -- -- 2018-07-31
Tachlit TTF TA 90 177780 0.11% 1737 0.99% 2017-07-31
BlackRock Russell 2500 197219 0.14% 197219 -- 2018-06-30
Vanguard Instl Ttl Stk Mkt Idx InstlPls 238638 0.16% -- -- 2018-07-31
Fidelity Spartan 225599 0.15% -- -- 2018-07-31
AXA 2000 Managed Volatility K 212046 0.14% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 3655516 2.39% 134800 3.83% 2018-07-31
The Vanguard Russell 2000 Growth Index 247932 0.16% -- -- 2018-07-31
Vanguard Health Care ETF 251134 0.16% 2142 0.86% 2018-07-31
Schwab Small Cap Index 261100 0.17% -- -- 2018-07-31
BlackRock Extended Equity Market K 232548 0.16% 102342 78.60% 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 340768 0.22% 1286 0.38% 2018-07-31
iShares Micro-Cap 374397 0.39% -- -- 2018-09-12
Bridgeway Ultra-Small Company Market 387000 0.27% 335000 644.23% 2018-06-30
iShares Russell 2000 Growth 1385723 1.44% -1336 -0.10% 2018-09-12
Vanguard Extended Market Idx Inv 1650316 1.08% -- -- 2018-07-31
iShares Nasdaq Biotechnology 1576788 1.64% -3003 -0.19% 2018-09-12
CREF Stock R1 216227 0.15% 216227 -- 2018-06-30
Vanguard Growth & Income Inv 225800 0.18% 73519 48.28% 2018-03-31
Vanguard Russell 2000 ETF 155741 0.11% 155741 -- 2018-06-30
Schwab US Broad Market ETF 64178 0.04% -- -- 2018-07-12
BNY Mellon EB DL Mkt Completion 54977 0.04% -- -- 2018-03-31
Northern Small Cap Index 82369 0.06% 82369 -- 2018-06-30
Vanguard Balanced Index Inv 55150 0.04% 32150 139.78% 2018-05-31
iShares Russell 3000 49611 0.03% 172 0.35% 2018-07-02
ProShares Ultra Nasdaq Biotechnology 54073 0.04% -5766 -9.64% 2018-06-30
BlackRock U.S. Equity Market F 29860 0.02% 3165 11.86% 2018-03-31
iShares Core S&P Total US Stock Mkt 31915 0.02% -- -- 2018-06-14
SSgA U.S. Total Market Index Fd Class I 18484 0.02% 9109 97.16% 2017-12-31
The Vanguard Total Stock Market Index 20226 0.02% -- -- 2018-03-31
DFA US Small Cap I 25021 0.02% -- -- 2018-02-28
USAA Extended Market Index 17465 0.01% -- -- 2018-02-28
FlexShares Mstar US Mkt Factors Tilt ETF 21340 0.02% -- -- 2018-02-27
BNY Mellon Market Completion Fund UC1 54977 0.05% 52223 1896.26% 2017-09-30
Bruce 114927 0.10% 114927 -- 2017-10-31
Vanguard Small Cap Index 3477124 0.73% -3376883 -49.27% 2016-12-31
Vanguard Small Cap Growth Index Inv 1930123 0.40% -2006021 -50.96% 2016-12-31
TIAA-CREF Small-Cap Blend Idx Inst 342895 0.07% -- -- 2016-12-31
SPDR® S&P Biotech ETF 6398160 1.10% 41800 0.70% 2015-11-19
iShares Russell 2000 (AU) 3934384 0.70% -4962 -0.10% 2015-11-19
Vanguard Small Cap Growth Index Fund 3218182 0.80% -55568 -1.70% 2015-10-31
PowerShares Dynamic Biotech&Genome Port 3211221 0.60% -- -- 2015-11-19
Fidelity Advisor® Biotechnology Fund 1151662 0.30% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 991550 0.20% -- -- 2015-09-30
CREF Stock Account 865904 0.20% -- -- 2015-09-30
American Century Small Company Fund 676464 0.20% 541277 400.40% 2015-09-30
Fidelity® Select Biotechnology Portfolio 8063306 1.90% -- -- 2015-09-30

Christine Ann Mundkur Ms. Christine A. Mundkur is an Independent Non-Executive Director at Lupin Ltd. and an Independent Director at MannKind Corp. She is on the Board of Directors at Lupin Ltd. and MannKind Corp. Ms. Mundkur was previously employed as a Chairman & Chief Executive Officer by Impopharma, Inc., a President & Chief Executive Officer by Sandoz, Inc., a Chief Executive Officer by Barr Laboratories, Inc., and a SEVP-Global Quality, Safety & Regulatory Affairs by Barr Pharmaceuticals, Inc. She also served on the board at Uman Pharma, Inc. She received her undergraduate degree from St. Louis University and a graduate degree from Saint Louis University School of Law.
Ronald J. Consiglio Mr. Ronald J. Consiglio, CPA, is an Independent Director at MannKind Corp., a Trustee at Metropolitan West Funds and a Managing Director at Synergy Trading LLC. He is on the Board of Directors at MannKind Corp. Mr. Consiglio was previously employed as a Chief Financial Officer & Executive Vice President by Trading Edge, Inc., a Chief Executive Officer by Angeles Mortgage Investment Trust, and a Chief Financial Officer, Director & Senior VP by Cantor Fitzgerald & Co. He also served on the board at Natrol, Inc. He received his undergraduate degree from California State University-Northridge.
Stuart A. Tross Currently, Stuart A. Tross is Chief People & Workplace Officer at MannKind Corp. In his past career he held the position of Vice President-Global Human Resources at Bristol-Myers Squibb Co., Senior Vice President-Human Resources of Amgen, Inc., Management Consultant at Towers Perrin, Inc. and Global Head-Human Resources at Mead Johnson & Co. LLC. Dr. Tross received a graduate degree from Spalding University, Inc., an undergraduate degree from Cornell University and a doctorate and a graduate degree from Georgia Institute of Technology.
Kent Kresa Founder of Northrop Grumman Corp., Kent Kresa is a businessperson who has been at the head of 6 different companies and is Chairman for MannKind Corp. He is also Chairman for California Institute of Technology, Member of National Academy of Engineering and Principal at the University of California, Los Angeles and on the board of 7 other companies. He previously held the position of Non-Executive Chairman for Avery Dennison Corp., Director at General Motors Corp. and Senior Advisor at The Carlyle Group LP (Corporate Private Equity). Kent Kresa received an undergraduate degree, a graduate degree and an undergraduate degree from Massachusetts Institute of Technology.
Kent Kresa Founder of Northrop Grumman Corp., Kent Kresa is a businessperson who has been at the head of 6 different companies and is Chairman for MannKind Corp. He is also Chairman for California Institute of Technology, Member of National Academy of Engineering and Principal at the University of California, Los Angeles and on the board of 7 other companies. He previously held the position of Non-Executive Chairman for Avery Dennison Corp., Director at General Motors Corp. and Senior Advisor at The Carlyle Group LP (Corporate Private Equity). Kent Kresa received an undergraduate degree, a graduate degree and an undergraduate degree from Massachusetts Institute of Technology.
Henry L. Nordhoff Henry L. Nordhoff is a businessperson who has been the head of 6 different companies. Mr. Nordhoff occupies the position of Chairman & Chief Executive Officer of Banyan Biomarkers, Inc., Chairman for Proactive Diagnostics, Managing Director at Shipston Group Ltd. and Chairman for Chugai Pharma USA LLC. Mr. Nordhoff is also on the board of MannKind Corp. and Sanford Burnham Prebys Medical Discovery Institute. In the past he held the position of Non-Executive Chairman of Gen-Probe, Inc., Executive Chairman for Cypher Genomics, Inc. and President & Chief Executive Officer of Targetech, Inc. Mr. Nordhoff received an undergraduate degree from The Johns Hopkins University and an MBA from Columbia University.
Michael A. Friedman Dr. Michael A. Friedman, MD, is an Independent Director at Intuitive Surgical, Inc., an Independent Director at Celgene Corp., an Independent Director at MannKind Corp., a Chief Executive Officer-Emeritus at City of Hope National Medical Center, an Associate Director at National Cancer Institute and an Independent Non-Executive Director at Smith & Nephew A/S (Denmark). He is on the Board of Directors at Sermonix Pharmaceuticals LLC, Intuitive Surgical, Inc., Celgene Corp., MannKind Corp., California Institute for Regenerative Medicine, Smith & Nephew A/S (Denmark) and Tulane University (Louisiana). Dr. Friedman was previously employed as an Independent Non-Executive Director by Smith & Nephew Plc, a Senior Vice President by G.D. Searle & Co., Inc., a SVP-Medical, Public Policy, Research & Development by Pharmacia Corp., a Deputy Commissioner-Operations by US Food & Drug Administration, an Associate Director by National Institutes of Health, a Director-Cancer Research Institute by The University of California, San Francisco, and a Chief Medical Officer-Biomedical Preparedness by Pharmaceutical Research & Manufacturers of America. He also served on the board at California Healthcare Institute, Cancer Research Institute, National Comprehensive Cancer Network, Inc. and Rite Aid Corp. He received his undergraduate degree from Tulane University (Louisiana) and a doctorate degree from The University of Texas Southwestern Medical Center.
David M. Kendall Currently, David M. Kendall holds the position of Chief Medical Officer for MannKind Corp. In the past Dr. Kendall was Medical Director for International Diabetes Center, Vice President-Global Medical Affairs at Eli Lilly & Co. and Vice President-Global Medical Affairs at Lilly Diabetes (a subsidiary of Eli Lilly & Co.), Director & Medical Director at Park Nicollet Health Services, Inc., Medical Director at Amylin Pharmaceuticals, Inc. and Chief Scientific & Medical Affairs Officer at American Diabetes Association. David M. Kendall received a doctorate from the University of Minnesota and an undergraduate degree from St. Olaf College.
James Samuel Shannon Dr. James S. Shannon, MD, is an Independent Director at Horizon Therapeutics Plc, a Member-Supervisory Board at ProQR Therapeutics NV, an Independent Director at MannKind Corp. and a Member at The Royal College of Physicians. He is on the Board of Directors at Horizon Therapeutics Plc, ProQR Therapeutics NV, Impatients N.V., Immodulon Therapeutics Ltd. and MannKind Corp. Dr. Shannon was previously employed as a Chief Medical Officer by GlaxoSmithKline Plc, a Non-Executive Director by Circassia Ltd., a Member-Supervisory Board by Crucell NV, an Independent Director by MannKind Corp., an Independent Director by Endocyte, Inc., a President, Chief Executive Officer & Director by Costes Pharmaceuticals, Inc., a Global Head-Drug Development by Novartis Pharma AG, a Head-Drug Regulatory Affairs by Sandoz Ltd., and a Senior Vice President-Clinical Development by Sterling Winthrop, Inc. He also served on the board at Biotie Therapies Oyj, Arch Therapeutics, Inc. /Old/, ViiV Healthcare Ltd. and Xanodyne Pharmaceuticals, Inc. He received his undergraduate degree from Queen's University of Belfast, a graduate degree from Queen's University of Belfast and a doctorate degree from Queen's University of Belfast.
David B. Thomson Currently, David B. Thomson holds the position of Secretary, Vice President & General Counsel of MannKind Corp. Dr. Thomson received a doctorate, a graduate degree and an undergraduate degree from Queen's University and a graduate degree from the University of Toronto.
Joseph Saldanha Mr. Joseph Saldanha is a Chief Business Officer at Valeritas Holdings, Inc., a Vice President-Marketing & Business Development at MannKind Corp. and a General Manager-Julphar Diabetes Division at Gulf Pharmaceutical Industries. He received his undergraduate degree from Drexel University and a graduate degree from the University of Pennsylvania.
Joseph Kocinsky Joseph Kocinsky is Chief Technology Officer of MannKind Corp. Mr. Kocinsky received an undergraduate degree and a graduate degree from New Jersey Institute of Technology and an MBA from Seton Hall University.
Rosabel Realica Alinaya Presently, Rosabel Realica Alinaya is Senior VP-Investor Relations & Treasury at MannKind Corp. She is also Member of The American Institute of Certified Public Accountants and Member of California Society of Certified Public Accountants. She received an undergraduate degree from The California State University.
Michael E. Castagna Dr. Michael E. Castagna is a Chief Executive Officer & Director at MannKind Corp. He is on the Board of Directors at MannKind Corp. and Pet Partners. Dr. Castagna was previously employed as a Vice President-Global Commercial by Amgen, Inc., an Executive Director-Immunology Franchise by Bristol-Myers Squibb Co., and a VP, Head-North America Biopharmaceuticals by Novartis AG. He received his undergraduate degree from Philadelphia College of Pharmacy, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from Massachusetts College of Pharmacy & Health Science.
Michael E. Castagna Dr. Michael E. Castagna is a Chief Executive Officer & Director at MannKind Corp. He is on the Board of Directors at MannKind Corp. and Pet Partners. Dr. Castagna was previously employed as a Vice President-Global Commercial by Amgen, Inc., an Executive Director-Immunology Franchise by Bristol-Myers Squibb Co., and a VP, Head-North America Biopharmaceuticals by Novartis AG. He received his undergraduate degree from Philadelphia College of Pharmacy, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from Massachusetts College of Pharmacy & Health Science.
James P. McCauley James P. McCauley is Chief Commercial Officer of MannKind Corp. Mr. McCauley received an MBA from Kellogg School of Management, an undergraduate degree from the University of Notre Dame and a graduate degree from South Texas College of Law.
Steven Binder Presently, Steven Binder occupies the position of CFO & Principal Accounting Officer of MannKind Corp. In the past he was Chief Financial Officer & Vice President at Stryker Corp., Vice President-Finance at Bristol-Myers Squibb Co. Vice President-Finance of Bristol-Myers Squibb Pharmaceuticals Ltd. and Vice President-Finance of Bristol-Myers Squibb KK (both are subsidiaries of Bristol-Myers Squibb Co.) and Vice President-Strategic Development at Oncology Therapeutics Network Corp. Mr. Binder received an undergraduate degree from Muhlenberg College.
Courtney Barton Currently, Courtney Barton holds the position of Chief Compliance & Privacy Officer, Vice President at MannKind Corp. In the past Ms. Barton occupied the position of Chief Compliance Officer of Anacor Pharmaceuticals, Inc. She received an undergraduate degree from Syracuse University.
Elizabeth G. Ingram Elizabeth G. Ingram holds the position of Chief Marketing Officer for MannKind Corp. In her past career Ms. Ingram was Senior Vice President-Managed Market at DexCom, Inc. and Vice President-Market Access Strategy at Bristol-Myers Squibb Co. Ms. Ingram received an undergraduate degree from East Carolina University and a graduate degree from the University of South Carolina.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐